Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders

Overview

Journal Biol Blood Marrow Transplant

Date 2017 Jun 13

PMID 28602958

Citations 22

Authors

Lauri M Burroughs

Akiko Shimamura

Julie-An Talano

Jennifer A Domm

Kelsey K Baker

Colleen Delaney

Haydar Frangoul

David A Margolis

K Scott Baker

Eneida R Nemecek

Amy E Geddis

Brenda M Sandmaier

H Joachim Deeg

Rainer Storb

Ann E Woolfrey

Affiliations

Soon will be listed here.

Abstract

Hematopoietic cell transplantation (HCT) is effective in the treatment of inherited marrow failure disorders and other nonmalignant diseases. Conventional myeloablative conditioning regimens have been associated with high transplant-related mortality, particularly in patients with comorbid conditions. Here we report on 14 patients with marrow failure disorders (Shwachman-Diamond syndrome, n = 3; Diamond Blackfan anemia, n = 4; GATA2 deficiency, n = 2; paroxysmal nocturnal hemoglobinuria, n = 4; and an undefined marrow failure disorder, n = 1) who underwent HCT on a prospective, phase II, multicenter clinical trial. Patients were given HLA-matched related (n = 2) or unrelated (n = 12) grafts after conditioning with treosulfan (42 g/m), fludarabine (150 mg/m), ± thymoglobulin (n = 11; 6 mg/kg). All patients engrafted. At a median follow-up of 3 years, 13 patients are alive with complete correction of their underlying disease. These results indicate that the combination of treosulfan, fludarabine, and thymoglobulin is effective at establishing donor engraftment with a low toxicity profile and excellent disease-free survival in patients with marrow failure disorders.

Citing Articles

Reduced toxicity conditioning for hematopoietic stem cell transplantation in children with Diamond-Blackfan anemia.

Qudeimat A, Suryaprakash S, Madden R, Srinivasan A, Wlodarski M, Bhoopalan S Haematologica. 2024; 109(10):3404-3407.

PMID: 38813735 PMC: 11443391. DOI: 10.3324/haematol.2024.285147.

Minimal intensity conditioning strategies for bone marrow failure: is it time for "preventative" transplants?.

Agarwal S Hematology Am Soc Hematol Educ Program. 2023; 2023(1):135-140.

PMID: 38066900 PMC: 10727038. DOI: 10.1182/hematology.2023000470.

Posttransplant complications in patients with marrow failure syndromes: are we improving long-term outcomes?.

Hudda Z, Myers K Hematology Am Soc Hematol Educ Program. 2023; 2023(1):141-148.

PMID: 38066882 PMC: 10727016. DOI: 10.1182/hematology.2023000471.

Pediatric Bone Marrow Failure: A Broad Landscape in Need of Personalized Management.

Vissers L, van der Burg M, Lankester A, Smiers F, Bartels M, Mohseny A J Clin Med. 2023; 12(22).

PMID: 38002797 PMC: 10672506. DOI: 10.3390/jcm12227185.

Treosulfan vs busulfan conditioning for allogeneic bmt in children with nonmalignant disease: a randomized phase 2 trial.

Sykora K, Beier R, Schulz A, Cesaro S, Greil J, Gozdzik J Bone Marrow Transplant. 2023; 59(1):107-116.

PMID: 37925531 PMC: 10781637. DOI: 10.1038/s41409-023-02135-9.

References

Raiola A, Van Lint M, Lamparelli T, Gualandi F, Benvenuto F, Figari O . Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria. Haematologica. 2000; 85(1):59-62. View

Nash R, Antin J, Karanes C, Fay J, Avalos B, Yeager A . Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 2000; 96(6):2062-8. View

Woodard P, Wang W, Pitts N, Benaim E, Horwitz E, Cunningham J . Successful unrelated donor bone marrow transplantation for paroxysmal nocturnal hemoglobinuria. Bone Marrow Transplant. 2001; 27(6):589-92. DOI: 10.1038/sj.bmt.1702827. View

Hegenbart U, Niederwieser D, Forman S, Holler E, Leiblein S, Johnston L . Hematopoietic cell transplantation from related and unrelated donors after minimal conditioning as a curative treatment modality for severe paroxysmal nocturnal hemoglobinuria. Biol Blood Marrow Transplant. 2003; 9(11):689-97. DOI: 10.1016/s1083-8791(03)00264-7. View

Kawahara K, Witherspoon R, Storb R . Marrow transplantation for paroxysmal nocturnal hemoglobinuria. Am J Hematol. 1992; 39(4):283-8. DOI: 10.1002/ajh.2830390409. View

Donadieu J, Michel G, Merlin E, Bordigoni P, Monteux B, Beaupain B . Hematopoietic stem cell transplantation for Shwachman-Diamond syndrome: experience of the French neutropenia registry. Bone Marrow Transplant. 2005; 36(9):787-92. PMC: 7091863. DOI: 10.1038/sj.bmt.1705141. View

Cesaro S, Oneto R, Messina C, Gibson B, Buzyn A, Steward C . Haematopoietic stem cell transplantation for Shwachman-Diamond disease: a study from the European Group for blood and marrow transplantation. Br J Haematol. 2005; 131(2):231-6. DOI: 10.1111/j.1365-2141.2005.05758.x. View

Filipovich A, Weisdorf D, Pavletic S, Socie G, Wingard J, Lee S . National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005; 11(12):945-56. DOI: 10.1016/j.bbmt.2005.09.004. View

Deeg H, Storer B, Boeckh M, Martin P, McCune J, Myerson D . Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant. 2006; 12(5):573-84. DOI: 10.1016/j.bbmt.2005.12.036. View

10.

Sauer M, Zeidler C, Meissner B, Rehe K, Hanke A, Welte K . Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman-Diamond syndrome. Bone Marrow Transplant. 2007; 39(3):143-7. DOI: 10.1038/sj.bmt.1705553. View

11.

Greystoke B, Bonanomi S, Carr T, Gharib M, Khalid T, Coussons M . Treosulfan-containing regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities. Br J Haematol. 2008; 142(2):257-62. DOI: 10.1111/j.1365-2141.2008.07064.x. View

12.

Bhatla D, Davies S, Shenoy S, Harris R, Crockett M, Shoultz L . Reduced-intensity conditioning is effective and safe for transplantation of patients with Shwachman-Diamond syndrome. Bone Marrow Transplant. 2008; 42(3):159-65. DOI: 10.1038/bmt.2008.151. View

13.

Bernardo M, Zecca M, Piras E, Vacca A, Giorgiani G, Cugno C . Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major. Br J Haematol. 2008; 143(4):548-51. DOI: 10.1111/j.1365-2141.2008.07385.x. View

14.

Walters M, Hardy K, Edwards S, Adamkiewicz T, Barkovich J, Bernaudin F . Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2009; 16(2):263-72. PMC: 2919571. DOI: 10.1016/j.bbmt.2009.10.005. View

15.

Nemecek E, Guthrie K, Sorror M, Wood B, Doney K, Hilger R . Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol Blood Marrow Transplant. 2010; 17(3):341-50. PMC: 2974965. DOI: 10.1016/j.bbmt.2010.05.007. View

16.

Smith A, Majhail N, MacMillan M, DeFor T, Jodele S, Lehmann L . Hematopoietic cell transplantation comorbidity index predicts transplantation outcomes in pediatric patients. Blood. 2011; 117(9):2728-34. DOI: 10.1182/blood-2010-08-303263. View

17.

Slatter M, Rao K, Amrolia P, Flood T, Abinun M, Hambleton S . Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience. Blood. 2011; 117(16):4367-75. DOI: 10.1182/blood-2010-10-312082. View

18.

Kasai K, Nakamura Y, White R . Amplification of a variable number of tandem repeats (VNTR) locus (pMCT118) by the polymerase chain reaction (PCR) and its application to forensic science. J Forensic Sci. 1990; 35(5):1196-200. View

19.

Bernardo M, Piras E, Vacca A, Giorgiani G, Zecca M, Bertaina A . Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Blood. 2012; 120(2):473-6. DOI: 10.1182/blood-2012-04-423822. View

20.

Tsai P, Sahdev I, Herry A, Lipton J . Fatal cyclophosphamide-induced congestive heart failure in a 10-year-old boy with Shwachman-Diamond syndrome and severe bone marrow failure treated with allogeneic bone marrow transplantation. Am J Pediatr Hematol Oncol. 1990; 12(4):472-6. DOI: 10.1097/00043426-199024000-00012. View